Avidity’s affinity for muscle

Avidity Biosciences LLC has developed a strategy for delivering siRNA and antisense therapies to tissues outside the liver and has preclinical proof-of-concept for two molecules that target muscle. The company has set its next sights on lymphocyte delivery.

Avidity is creating a new class of antibody-drug conjugate (ADC) it calls antibody-siRNA conjugates (ASCs), using the highly specific targeting of antibodies to deliver the nucleic acids to tissue-specific cell markers, and relying on endocytosis to internalize the active agent (see “Muscling Up”)...